Expression of Vascular Endothelial Growth Factor and Its Role in Oncogenesis of Human Gastric Carcinoma

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2002 Jan 31

PMID 11819817

Citations 30

Authors

D H Liu

X Y Zhang

D M Fan

Y X Huang

J S Zhang

W Q Huang

Y Q Zhang

Q S Huang

W Y Ma

Y B Chai

M Jin

Affiliations

Soon will be listed here.

Abstract

Aim: To establish the role of vascular endothelial growth factor (VEGF) in the oncogenesis of human gastric carcinoma more directly.

Methods: The expression of VEGF and its receptor kinase-domain insert containing receptor (KDR) in human gastric cancer tissue were observed by immunohistochemical staining. VEGF levels were manipulated in human gastric cancer cell using eukaryotic expression constructs designed to express the complete VEGF(165) complimentary DNA in either the sense or antisense orientation. The biological changes of the cells were observed in which VEGF was up-regulated or down-regulated.

Results: VEGF-positive rate was 50%, and VEGF was mainly localized in the cytoplasm and membrane of the tumor cells, while KDR was mainly located in the membrane of vascular endothelial cells in gastric cancer tissues and peri-cancerous tissue. In 2 cases of 50 specimens, the gastric cancer cells expressed KDR, localized in both the cytoplasm and membrane. Introduction of VEGF(165) antisense into human gastric cancer cells (SGC-7901, immunofluorescence intensity, 31.6%)) resulted in a significant reduction in VEGF-specific messenger RNA and total and cell surface VEGF protein (immunofluorescence intensity, 8.9%) (P<0.05). Conversely, stable integration of VEGF(165) in the sense orientation resulted in an increase in cellular and cell surface VEGF (immunofluorescence intensity, 75.4%) (P<0.05). Lowered VEGF levels were associated with a marked decrease in the growth of nude mouse xenografted tumor (at 33 days postimplantation, tumor volume: 345.40 +/- 136.31 mm3)(P<0.05 vs control SGC-7901 group: 1534.40 +/- 362.88 mm3), whereas up-regulation of VEGF resulted in increased xenografted tumor size (at 33 days postimplantation, tumor volume: 2350.50 +/- 637.70 mm3) (P<0.05 vs control SGC-7901 group).

Conclusion: This study provides direct evidence that VEGF plays an important role in the oncogenesis of human gastric cancer.

Citing Articles

Calreticulin regulates vascular endothelial growth factor-A mRNA stability in gastric cancer cells.

Lee P, Chiang J, Chen C, Chien Y, Chen W, Huang C PLoS One. 2019; 14(11):e0225107.

PMID: 31725767 PMC: 6855450. DOI: 10.1371/journal.pone.0225107.

The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer.

Guan X, Zhao H, Niu J, Tang D, Ajani J, Wei Q BMC Gastroenterol. 2009; 9:77.

PMID: 19835575 PMC: 2771032. DOI: 10.1186/1471-230X-9-77.

Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer.

Guan X, Zhao H, Niu J, Tan D, Ajani J, Wei Q J Exp Clin Cancer Res. 2009; 28:94.

PMID: 19566948 PMC: 2717936. DOI: 10.1186/1756-9966-28-94.

Histopathological predictor for regional lymph node metastasis in gastric cancer.

Morita H, Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Nishimura C Virchows Arch. 2008; 454(2):143-51.

PMID: 19104832 DOI: 10.1007/s00428-008-0717-3.

Significance of vascular endothelial growth factor expression and its correlation with inducible nitric oxide synthase in gastric cancer.

Song Z, Wen S, Peng J, Huang X, Qian K World J Gastroenterol. 2004; 10(9):1250-5.

PMID: 15112337 PMC: 4622761. DOI: 10.3748/wjg.v10.i9.1250.

References

Kolch W, Heidecker G, Troppmair J, Yanagihara K, Bassin R, Rapp U . Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum. Oncogene. 1993; 8(2):361-70. View

Tsuzuki Y, Fukumura D, Oosthuyse B, Koike C, Carmeliet P, Jain R . Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. 2000; 60(22):6248-52. View

Saleh M, Stacker S, Wilks A . Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res. 1996; 56(2):393-401. View

Xu C, Pan B . Current status of gene therapy in gastroenterology. World J Gastroenterol. 2002; 4(1):85-89. PMC: 4767776. DOI: 10.3748/wjg.v4.i1.85. View

Inoue K, Ozeki Y, Suganuma T, Sugiura Y, Tanaka S . Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer. 1997; 79(2):206-13. DOI: 10.1002/(sici)1097-0142(19970115)79:2<206::aid-cncr2>3.0.co;2-i. View

Assy N, Paizi M, Gaitini D, Baruch Y, Spira G . Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension. World J Gastroenterol. 2002; 5(4):296-300. PMC: 4695538. DOI: 10.3748/wjg.v5.i4.296. View

Zhang L, Li S, Wang X . CEA and AFP expression in human hepatoma cells transfected with antisense IGF-I gene. World J Gastroenterol. 2002; 4(1):30-32. PMC: 4767758. DOI: 10.3748/wjg.v4.i1.30. View

Martiny-Baron G, Marme D . VEGF-mediated tumour angiogenesis: a new target for cancer therapy. Curr Opin Biotechnol. 1995; 6(6):675-80. DOI: 10.1016/0958-1669(95)80111-1. View

Neckers L, Kanekal M, Connell Y . Non-antisense oligonucleotide approaches for experimental treatment of glioblastoma. Antisense Nucleic Acid Drug Dev. 1998; 8(2):177-9. DOI: 10.1089/oli.1.1998.8.177. View

10.

Folkman J . Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg. 1972; 175(3):409-16. PMC: 1355186. DOI: 10.1097/00000658-197203000-00014. View

11.

Brogi E, Wu T, Namiki A, Isner J . Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation. 1994; 90(2):649-52. DOI: 10.1161/01.cir.90.2.649. View

12.

Maeda K, Chung Y, Ogawa Y, Takatsuka S, Kang S, Ogawa M . Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer. 1996; 77(5):858-63. DOI: 10.1002/(sici)1097-0142(19960301)77:5<858::aid-cncr8>3.0.co;2-a. View

13.

Kim K, Li B, Winer J, Armanini M, Gillett N, PHILLIPS H . Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993; 362(6423):841-4. DOI: 10.1038/362841a0. View

14.

Darius H, Buerke M, Boissel J, Grosser T, Veit K, Zacharowski K . [Local drug delivery and gene therapy]. Herz. 1998; 22(6):347-54. DOI: 10.1007/BF03044285. View

15.

Goldberg M, Schneider T . Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem. 1994; 269(6):4355-9. View

16.

Nguyen J . Vascular endothelial growth factor as a target for cancer gene therapy. Adv Exp Med Biol. 2000; 465:447-56. DOI: 10.1007/0-306-46817-4_39. View

17.

Kolch W, Heidecker G, Lloyd P, Rapp U . Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature. 1991; 349(6308):426-8. DOI: 10.1038/349426a0. View

18.

Li X, Wu J, He Z, Ma Q, Gao D . Overproduction of nitric oxide inhibits vascular reactivity in portal hypertensive rats. World J Gastroenterol. 2016; 3(4):221-4. PMC: 4806237. DOI: 10.3748/wjg.v3.i4.221. View

19.

Yuan J, Zhang R, Zhang R, Guo L, Wang X, Luo D . Growth-inhibiting effects of taxol on human liver cancer in vitro and in nude mice. World J Gastroenterol. 2002; 6(2):210-215. PMC: 4723486. DOI: 10.3748/wjg.v6.i2.210. View

20.

Mukhopadhyay D, Tsiokas L, Sukhatme V . Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res. 1995; 55(24):6161-5. View